Second Genome Inc.

secondgenome.com

Second Genome is at the cutting edge of microbiome science, translating breakthrough research into medicines and other novel products that help humanity. Our scientists and staff are true pioneers in this dynamic field. We are advancing a pipeline of novel therapies for serious diseases, while also making new breakthroughs in multiple fields of research using our one-of-a kind discovery platform. With our impact felt across industries — from healthcare and nutrition to agriculture — we are recognized as global leaders in translating rapidly emerging science into products that help humanity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

news image

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More

CELL AND GENE THERAPY

TERUMO BLOOD AND CELL TECHNOLOGIES TO COLLABORATE WITH CSL PLASMA ON U.S. FDA CLEARANCE OF PLASMA COLLECTION TECHNOLOGY

CSL Plasma | March 11, 2022

news image

CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval. The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologi...

Read More

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

news image

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

news image

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determinati...

Read More
news image

INDUSTRIAL IMPACT

SINTALICA BIOSCIENCE ANNOUNCES KEY APPROVAL MILESTONES FROM THE ITALIAN HEALTH AUTHORITY

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and...

Read More
news image

CELL AND GENE THERAPY

TERUMO BLOOD AND CELL TECHNOLOGIES TO COLLABORATE WITH CSL PLASMA ON U.S. FDA CLEARANCE OF PLASMA COLLECTION TECHNOLOGY

CSL Plasma | March 11, 2022

CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval. The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologi...

Read More
news image

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More
news image

CELL AND GENE THERAPY

PINNACLE FERTILITY PARTNERS WITH IGENOMIX AS THEIR EXCLUSIVE GENETICS LABORATORY AND GENETIC COUNSELING PROVIDER

Igenomix | June 08, 2022

Pinnacle Fertility (Pinnacle), the fastest-growing network of physician-centered fertility practices representing more than seven clinics and 20 locations nationwide, has partnered with Igenomix as their exclusive preimplantation genetics testing (PGT) laboratory and provider for genetic counseling services. Continuing Pinnacle's commitment to collaborative medical leadership and patient-first care, this strategic partnership was the result of the Medical Council's collective determinati...

Read More

Resources

resource image

INDUSTRIAL IMPACT

The US Bioeconomy

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

resource image

INDUSTRIAL IMPACT

The US Bioeconomy

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Document quality control emerges as a discipline in its own right

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us